SECONDARY PREVENTION OF SMALL SUBCORTICAL STROKES (SPS3)

小皮质下中风的二级预防 (SPS3)

• 批准号: 7607317
• 负责人: ANAND VAISHNAV
• 金额: $ 7.85万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607317
• 关键词: Antihypertensive Agents; Arteries; Aspirin; Blood Vessels; Cerebrum; Clinical; Computer Retrieval of Information on Scientific Projects Database; Disease; Event; Funding; Grant; Health Benefit; Hypertension; Hypotension; Impaired cognition; Institution; Patients; Range; Recurrence; Research; Research Personnel; Resources; Secondary Prevention; Source; Stroke; United States National Institutes of Health; Vascular Dementia; clopidogrel

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall aim of the Secondary Prevention of Small Subcortical Strokes (SPS3) project is to define efficacious therapies for cerebral small artery disease and its two most common clinical manifestations: small subcortical strokes (S3, also called lacunar strokes) and cognitive decline (vascular dementia). Optimal antiplatelet therapy and antihypertensive management of S3 patients to reduce stroke recurrence and cognitive decline has not been defined and is likely to yield important health benefits. Primary aims are to determine whether combination antiplatelet therapy consisting of aspirin plus clopidogrel is superior to aspirin for reducing recurrent stroke, cognitive decline and major vascular events. Also, to determine whether "intensive" blood pressure lowering to a specific target range is superior to "usual" hypertension management for reducing recurrent stroke, cognitive decline and major vascular events.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 小型皮质下卒中二级预防（SPS 3）项目的总体目标是确定脑小动脉疾病及其两种最常见临床表现的有效疗法：小型皮质下卒中（S3，也称为腔隙性卒中）和认知下降（血管性痴呆）。S3患者的最佳抗血小板治疗和抗高血压管理，以减少卒中复发和认知功能下降尚未确定，可能会产生重要的健康益处。主要目的是确定由阿司匹林加氯吡格雷组成的联合抗血小板治疗在减少复发性卒中、认知能力下降和主要血管事件方面是否上级阿司匹林。此外，确定“强化”血压降低到特定目标范围是否上级“常规”高血压管理，以减少复发性卒中，认知能力下降和主要血管事件。